Denial Rate Benchmarks for Infusion and Buy-and-Bill Practices

A practice manager pulls up a published denial benchmark to see how the clinic stacks up. The number looks reasonable, maybe even reassuring. The claim population behind it does not look anything like an infusion practice's book of business, which makes it the wrong number.

Why published denial benchmarks mislead infusion and buy-and-bill practices

That benchmark was likely built from physician practices where prior authorization is occasional rather than continuous, and where a denied claim means a lost professional fee rather than a drug the clinic already paid to acquire. General benchmarks accurately describe the populations they are built from, which are simply different from infusion practices.

The largest published denial datasets lean heavily on hospital claims, and hospital denials run on a different engine entirely: inpatient authorization disputes and medical necessity reviews tied to admission status. An outpatient infusion practice is fighting a different battle, one built around J-code accuracy, a prior authorization that has to be renewed mid-treatment, and drug-unit errors that have nothing to do with whether the patient needed the infusion. Comparing an infusion center's denial rate to a hospital-dominated benchmark is like grading a marathon runner against a sprinter's splits.

Benchmarks drawn from physician practices carry the same flaw, just at a smaller scale. A denial rate built from primary care visits and orthopedic procedures still doesn't carry the authorization burden or the cost exposure that defines infusion. Before a practice adopts any denial benchmark, the first question has to be what population generated it, and if the answer isn't other infusion and buy-and-bill operations, the number isn't a reference point but a distraction.

The shifting denial environment for infusion payer mixes

Denial rates across healthcare have gotten worse in recent years, but that deterioration hasn't landed evenly across payer types, and infusion practices sit in the part of the distribution taking the hardest hit. Medicare Advantage denial activity has climbed sharply, because of tighter medical-necessity edits, broader prior authorization requirements, and utilization review systems that increasingly run on algorithms rather than manual review. Commercial payers have drifted upward too, but far more gradually. Traditional Medicare has stayed closer to flat.

That spread matters because of who infusion practices actually bill. Specialty infusion payer mixes tend to run heavy on Medicare Advantage and commercial plans, the two categories where denial pressure is building fastest and where algorithmic review is most aggressive. Blended, industry-wide denial statistics bury that concentration. A number built across every payer type and every specialty will always look calmer than an infusion center's own aging report, because the infusion book is disproportionately exposed to the exact payer segment driving the increase.

A second shift compounds the first. Payers are denying fewer claims outright at submission and recovering more money after the fact, through post-payment takebacks and audits. So a practice's front-end denial rate can look flat, even improving, while net collections quietly erode behind it. For infusion practices tracking only the initial denial rate, that's a blind spot with real cash consequences: the number the dashboard shows can be calm at the exact moment the money walks out the back door.

What makes infusion denial risk structurally different

Infusion isn't a high-denial specialty sitting at the tail end of a normal distribution. It runs on a different billing structure altogether, one that produces denials through mechanisms that simply don't exist in the claim populations behind most published benchmarks.

Three things set it apart. The first is authorization lifecycle complexity: nearly every specialty infusion drug needs prior authorization specifying drug, dose, frequency, and duration, and that authorization has to be renewed on the payer's schedule, re-triggered whenever the regimen changes, and tracked against expiration dates that can fall in the middle of an active course of treatment. Primary care, orthopedics, and behavioral health billing don't carry anything close to that burden at scale.

The second is drug-cost exposure. Under buy-and-bill, the practice buys the drug before the payer ever adjudicates the claim. If a biologic claim gets denied, it can leave tens of thousands of dollars in acquisition cost unrecovered, sometimes more. A denial here is a cash-flow emergency attached to a drug that's already been administered and can't be returned to the shelf.

The third is the billing architecture itself, where a drug name, an NDC, an administered dose, and a CPT administration code all have to line up correctly on a single claim line before a payer will pay it.

A claim can be clinically correct, medically necessary, and documented exactly as it should be at the point of care, yet a payer can still deny it for reasons that happened upstream, such as an authorization that expired mid-cycle, or downstream, such as a billing unit error on the remittance. The clinical encounter was flawless. The claim still failed. That gap, between clinical quality and claim outcome, is what no general benchmark is built to capture, and it's a major reason prior authorization denials make up such a large and growing share of what infusion practices write off.

The specific prior authorization failure modes that generate the most infusion denials

Authorization failure isn't one problem with one fix. It occurs at different points in the treatment timeline, and each point has its own cause.

The most common failure happens mid-treatment. Infusion therapies run in cycles over weeks or months, and the original authorization often only covers a fixed number of sessions or a defined window. When the renewal doesn't go in on time, later sessions in the same course of treatment get delivered without a valid authorization on file, even though the first sessions were approved and nothing about the clinical plan changed.

A second failure happens before treatment even starts, when payers update their prior authorization requirement lists during the year without clearly flagging the change to infusion centers. A drug or code that didn't need authorization last quarter might need one now, and a center working off an outdated checklist walks straight into a denial it never saw coming.

A third failure happens at the handoff between authorization and billing. An authorization approved for one CPT or J-code doesn't automatically cover a different but clinically equivalent code used when the claim goes out. This comes up often when a biosimilar gets substituted for a reference product after the authorization was already secured under the original drug's code.

A fourth happens at the authorization request itself, when the submission goes in missing treatment history, lab values, or the specific medical necessity language a payer requires. The denial that follows has nothing to do with whether the treatment was appropriate. It's a paperwork failure dressed up as a clinical one.

Timing is making all of this harder to catch. Major payers have shortened peer-to-peer review and prior authorization decision windows, in some cases down to just days, while formal appeal deadlines have stayed where they were, weeks to months out. An infusion center reviewing denials on a weekly or biweekly cycle is increasingly discovering the short clock has already run out, turning a denial that should have been recoverable into a permanent write-off.

How J-code and buy-and-bill billing mechanics amplify denial costs

An infusion denial doesn't cost what a general practice denial costs. The dollar figure attached to it tracks the acquisition cost of a specialty drug the practice already bought, not a professional fee that was simply never collected, and that difference changes the entire risk calculation.

Buy-and-bill structures the exposure directly. The practice pays for the drug up front and gets reimbursed only after the payer adjudicates the claim, typically at the average sales price plus a margin, minus the mandatory sequestration cut. Reimbursement is usually pegged to an ASP figure calculated two quarters earlier, so if drug prices rise between that calculation and the day the drug gets administered, the practice absorbs the difference. A denial doesn't put that exposure on hold. It locks it in.

Biosimilars have turned into a live flashpoint inside this structure. Starting October 1, 2022 for biosimilars already on the market, and from the first calendar quarter of ASP payment for new ones, Medicare began paying qualifying biosimilars at a richer margin than the reference biologic, for a five-year window. That created a real financial incentive to switch patients onto biosimilars. But the switch has to be reflected in J-code updates across every formulary involved, and a biosimilar billed under the reference product's old J-code is a denial waiting to happen, regardless of how appropriate the clinical switch was.

J-codes generate denials on their own, independent of any authorization problem. A single claim line has to coordinate the drug name, the NDC, the administered dose, and the CPT administration code, and a mismatch anywhere in that chain, a billing unit error, a missing waste modifier (JW or JZ), an NDC that doesn't match the J-code, produces a denial that has nothing to do with whether the authorization was valid.

Underpayment is the quieter version of the same exposure. A biologic claim paid below the contracted rate loses far more in absolute dollars than the same percentage shortfall on a cheaper drug would. If you don't reconcile at the line level, that gap never gets caught, and it turns into a permanent loss sitting quietly inside accounts receivable.

Infusion-Specific Denial Rate Targets and AR Benchmarks

Once the general benchmarks are set aside, infusion and buy-and-bill practices need their own reference points, covering denial rate, AR days, and the composition of aged AR, each calibrated to the authorization complexity and drug-cost exposure that general numbers leave out.

On denial rate, top-quartile ambulatory infusion providers run below the industry midpoint because their authorization and billing processes catch problems before they become denials. A denial rate running well above that range in an infusion book points to a process breakdown, not ordinary payer friction. Authorization-specific denials need to be tracked apart from coding denials and eligibility denials. Lumping them together hides exactly which part of the operation is failing and makes the fix harder to find.

Underpayment detection separates strong infusion operations from average ones. Top performers catch and act on a meaningfully higher share of underpayments than typical centers do, and that gap compounds on high-cost biologic claims, where even a small percentage error can leave a large dollar amount unclaimed.

Authorization approval rate deserves tracking right alongside denial rate, because it's a leading indicator, not a lagging one. High-performing infusion centers post approval rates well above the industry average, and faster turnaround on authorization requests directly cuts the mid-cycle expiration risk that drives much of infusion's denial volume. Use these as reference points for calibrating an operation against practices facing the same structural risks, not as a universal scorecard to hit regardless of payer mix.

Payer mix as the variable that most distorts an infusion practice's denial rate relative to published benchmarks

Even an infusion-specific benchmark means little without adjusting for payer mix first. An infusion practice weighted toward Medicare Advantage will run a structurally higher denial rate than one weighted toward traditional Medicare, and holding both to the same target is an analytical mistake, not a measure of which practice runs better.

Medicare Advantage plans now deny at more than double the rate of traditional Medicare, and that behavior has become the primary force pushing denial benchmarks higher across every specialty, not just infusion. A practice whose payer mix skews heavily toward Medicare Advantage needs a materially different target than one built on traditional Medicare or commercial PPO business. Applying the same number to both practices grades the wrong practice against the wrong yardstick, so infusion centers that want an honest read on their own performance have to build their payer mix into the benchmark before they ever look at the result.